We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Teradyne (TER) Beats Earnings and Revenue Estimates in Q2
Read MoreHide Full Article
Teradyne Inc. (TER - Free Report) reported second-quarter 2017 earnings of 90 cents per share, surpassing the Zacks Consensus Estimate of 86 cents. Also, earnings increased 72% year over year.Adjusted earnings per share exclude one-time items but include stock-based compensation expense.
Following the second-quarter results, Teradyne’s share price surged 0.29%. Also, on a year to date basis, the stock has outperformed the industry it belongs to. It has returned 35.8% compared with the industry’s gain of 29.1%.
Revenues
Revenues of $696.9 million increased 52.5% sequentially and 31% year over year. Also, the figure came above the Zacks Consensus Estimate of $665.0 million and at the higher-end of management’s guided range of $660–$700 million.
Approximately 85% of revenues came from semiconductor testing platforms, 6% from Industrial Automation, 5% from system test business and the remaining 4% from wireless test business.
Bookings
Total orders amounted to $462 million, declining 22.4% sequentially.
On a sequential basis, only Wireless Test Group orders were up 11.1% to $30 million, while all others decreased. Semiconductor Test orders were down 22.5% year over year, Systems Test orders decreased 37%, while Industrial Automation orders were declined 26.7%.
Margins
Pro forma gross margin was 56%, down 200 basis points (bps) sequentially but up 280 bps year over year. The sequential decrease was due to an unfavorable mix.
Total adjusted operating expenses of $170.9 million increased 8.5% year over year. As a percentage of sales, both engineering & development expenses and selling & administrative expenses decreased. As a result, adjusted operating margin came in at 31.3%, up 860 bps sequentially and 790 bps year over year.
GAAP net income was $175.0 million in the first quarter against net loss of $223.5 million in the year-ago quarter. Excluding special items but including stock-based compensation expense, non-GAAP net income came in at $181.5 million or 90 cents per share compared with $111.7 million or 55 cents in the year-ago quarter.
Balance Sheet
Teradyne ended the quarter with cash and cash equivalents and marketable securities balance of $1.41 billion, up from $1.22 billion in the prior quarter. Trade receivables were $405.9 million, up from $315 million last quarter.
Cash flow from operations was $230.3 million compared with $61.1 million in the previous quarter. Capex was $23.9 million compared with $22.1 million in the first quarter.
Share Repurchase/Dividend
In the reported quarter, Teradyne spent $56.6 million on share repurchases and paid $13.9 million as dividend.
Q3 Guidance
Management expects third-quarter revenues in the range of $455–$485 million, decreasing 32.6% sequentially at the mid-point. The Zacks Consensus Estimate is pegged at $445.4 million.
Non-GAAP earnings per share from continuing operations are likely to be in the range of 39–46 cents. The Zacks Consensus Estimate is pegged at 42 cents. GAAP earnings are expected in the range of 35–42 cents.
Conclusion
Teradyne is a leading provider of automated test equipment. The company reported strong second-quarter results, with both the top line and the bottom line outperforming the respective Zacks Consensus Estimate.
Management expects strong demand in its core test businesses in the upcoming quarter. Given the popularity of its products, acquisition of Universal Robots and continuous design wins, we are optimistic about Teradyne’s performance in the long run. However, weakness in the wireless test market could be a near-term concern.
Lam Research delivered a positive earnings surprise of 4.44%, on average, in the trailing four quarters.
Applied Materials delivered a positive earnings surprise of 3.35%, on average, in the trailing four quarters.
Fortive Corporation delivered a positive earnings surprise of 5.80%, on average, in the trailing four quarters.
More Stock News: 8 Companies Verge on Apple-Like Run
Did you miss Apple's 9X stock explosion after they launched their iPhone in 2007? Now 2017 looks to be a pivotal year to get in on another emerging technology expected to rock the market. Demand could soar from almost nothing to $42 billion by 2025. Reports suggest it could save 10 million lives per decade which could in turn save $200 billion in U.S. healthcare costs.
A bonus Zacks Special Report names this breakthrough and the 8 best stocks to exploit it. Like Apple in 2007, these companies are already strong and coiling for potential mega-gains. Click to see them right now >>
Unique Zacks Analysis of Your Chosen Ticker
Pick one free report - opportunity may be withdrawn at any time
Image: Bigstock
Teradyne (TER) Beats Earnings and Revenue Estimates in Q2
Teradyne Inc. (TER - Free Report) reported second-quarter 2017 earnings of 90 cents per share, surpassing the Zacks Consensus Estimate of 86 cents. Also, earnings increased 72% year over year.Adjusted earnings per share exclude one-time items but include stock-based compensation expense.
Following the second-quarter results, Teradyne’s share price surged 0.29%. Also, on a year to date basis, the stock has outperformed the industry it belongs to. It has returned 35.8% compared with the industry’s gain of 29.1%.
Revenues
Revenues of $696.9 million increased 52.5% sequentially and 31% year over year. Also, the figure came above the Zacks Consensus Estimate of $665.0 million and at the higher-end of management’s guided range of $660–$700 million.
Approximately 85% of revenues came from semiconductor testing platforms, 6% from Industrial Automation, 5% from system test business and the remaining 4% from wireless test business.
Bookings
Total orders amounted to $462 million, declining 22.4% sequentially.
On a sequential basis, only Wireless Test Group orders were up 11.1% to $30 million, while all others decreased. Semiconductor Test orders were down 22.5% year over year, Systems Test orders decreased 37%, while Industrial Automation orders were declined 26.7%.
Margins
Pro forma gross margin was 56%, down 200 basis points (bps) sequentially but up 280 bps year over year. The sequential decrease was due to an unfavorable mix.
Total adjusted operating expenses of $170.9 million increased 8.5% year over year. As a percentage of sales, both engineering & development expenses and selling & administrative expenses decreased. As a result, adjusted operating margin came in at 31.3%, up 860 bps sequentially and 790 bps year over year.
GAAP net income was $175.0 million in the first quarter against net loss of $223.5 million in the year-ago quarter. Excluding special items but including stock-based compensation expense, non-GAAP net income came in at $181.5 million or 90 cents per share compared with $111.7 million or 55 cents in the year-ago quarter.
Balance Sheet
Teradyne ended the quarter with cash and cash equivalents and marketable securities balance of $1.41 billion, up from $1.22 billion in the prior quarter. Trade receivables were $405.9 million, up from $315 million last quarter.
Cash flow from operations was $230.3 million compared with $61.1 million in the previous quarter. Capex was $23.9 million compared with $22.1 million in the first quarter.
Share Repurchase/Dividend
In the reported quarter, Teradyne spent $56.6 million on share repurchases and paid $13.9 million as dividend.
Q3 Guidance
Management expects third-quarter revenues in the range of $455–$485 million, decreasing 32.6% sequentially at the mid-point. The Zacks Consensus Estimate is pegged at $445.4 million.
Non-GAAP earnings per share from continuing operations are likely to be in the range of 39–46 cents. The Zacks Consensus Estimate is pegged at 42 cents. GAAP earnings are expected in the range of 35–42 cents.
Conclusion
Teradyne is a leading provider of automated test equipment. The company reported strong second-quarter results, with both the top line and the bottom line outperforming the respective Zacks Consensus Estimate.
Management expects strong demand in its core test businesses in the upcoming quarter. Given the popularity of its products, acquisition of Universal Robots and continuous design wins, we are optimistic about Teradyne’s performance in the long run. However, weakness in the wireless test market could be a near-term concern.
Teradyne, Inc. Price, Consensus and EPS Surprise
Teradyne, Inc. Price, Consensus and EPS Surprise | Teradyne, Inc. Quote
Other Stocks to Consider
Currently, Teradyne has a Zacks Rank #3 (Hold). Some better-ranked stocks in the same space are Lam Research Corporation (LRCX - Free Report) , carrying a Zacks Rank #1, and Applied Materials (AMAT - Free Report) and Fortive Corporation (FTV - Free Report) , carrying a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Lam Research delivered a positive earnings surprise of 4.44%, on average, in the trailing four quarters.
Applied Materials delivered a positive earnings surprise of 3.35%, on average, in the trailing four quarters.
Fortive Corporation delivered a positive earnings surprise of 5.80%, on average, in the trailing four quarters.
More Stock News: 8 Companies Verge on Apple-Like Run
Did you miss Apple's 9X stock explosion after they launched their iPhone in 2007? Now 2017 looks to be a pivotal year to get in on another emerging technology expected to rock the market. Demand could soar from almost nothing to $42 billion by 2025. Reports suggest it could save 10 million lives per decade which could in turn save $200 billion in U.S. healthcare costs.
A bonus Zacks Special Report names this breakthrough and the 8 best stocks to exploit it. Like Apple in 2007, these companies are already strong and coiling for potential mega-gains. Click to see them right now >>